BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

432 related articles for article (PubMed ID: 25872159)

  • 21. In Silico Modeling Approach for the Evaluation of Gastrointestinal Dissolution, Supersaturation, and Precipitation of Posaconazole.
    Hens B; Pathak SM; Mitra A; Patel N; Liu B; Patel S; Jamei M; Brouwers J; Augustijns P; Turner DB
    Mol Pharm; 2017 Dec; 14(12):4321-4333. PubMed ID: 28817288
    [TBL] [Abstract][Full Text] [Related]  

  • 22. An in vitro-in silico-in vivo approach to predicting the oral pharmacokinetic profile of salts of weak acids: case example dantrolene.
    Kambayashi A; Dressman JB
    Eur J Pharm Biopharm; 2013 May; 84(1):200-7. PubMed ID: 23262163
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prediction of in-vivo pharmacokinetic profile for immediate and modified release oral dosage forms of furosemide using an in-vitro-in-silico-in-vivo approach.
    Otsuka K; Wagner C; Selen A; Dressman J
    J Pharm Pharmacol; 2015 May; 67(5):651-65. PubMed ID: 25644429
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Once-daily atazanavir/cobicistat and darunavir/cobicistat exposure over 72 h post-dose in plasma, urine and saliva: contribution to drug pharmacokinetic knowledge.
    Elliot ER; Amara A; Pagani N; Else L; Moyle G; Schoolmeesters A; Higgs C; Khoo S; Boffito M
    J Antimicrob Chemother; 2017 Jul; 72(7):2035-2041. PubMed ID: 28407075
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Development of a Unified Dissolution and Precipitation Model and Its Use for the Prediction of Oral Drug Absorption.
    Jakubiak P; Wagner B; Grimm HP; Petrig-Schaffland J; Schuler F; Alvarez-Sánchez R
    Mol Pharm; 2016 Feb; 13(2):586-98. PubMed ID: 26674605
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Quantitative prediction of formulation-specific food effects and their population variability from in vitro data with the physiologically-based ADAM model: a case study using the BCS/BDDCS Class II drug nifedipine.
    Patel N; Polak S; Jamei M; Rostami-Hodjegan A; Turner DB
    Eur J Pharm Sci; 2014 Jun; 57():240-9. PubMed ID: 24060671
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Utilizing in vitro and PBPK tools to link ADME characteristics to plasma profiles: case example nifedipine immediate release formulation.
    Wagner C; Thelen K; Willmann S; Selen A; Dressman JB
    J Pharm Sci; 2013 Sep; 102(9):3205-19. PubMed ID: 23696038
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of surfactants, gastric emptying, and dosage form on supersaturation of dipyridamole in an in vitro model simulating the stomach and duodenum.
    Mitra A; Fadda HM
    Mol Pharm; 2014 Aug; 11(8):2835-44. PubMed ID: 25025699
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Identification of intestinal loss of a drug through physiologically based pharmacokinetic simulation of plasma concentration-time profiles.
    Peters SA
    Clin Pharmacokinet; 2008; 47(4):245-59. PubMed ID: 18336054
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Interplay of Adsorption, Supersaturation and the Presence of an Absorptive Sink on Drug Release from Mesoporous Silica-Based Formulations.
    Hate SS; Reutzel-Edens SM; Taylor LS
    Pharm Res; 2020 Aug; 37(8):163. PubMed ID: 32754797
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A combined in vitro in-silico approach to predict the oral bioavailability of borderline BCS Class II/IV weak base albendazole and its main metabolite albendazole sulfoxide.
    Pettarin M; Bolger MB; Chronowska M; Kostewicz ES
    Eur J Pharm Sci; 2020 Dec; 155():105552. PubMed ID: 32937212
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Meal Effects Confound Attempts to Counteract Rabeprazole-Induced Hypochlorhydria Decreases in Atazanavir Absorption.
    Faber KP; Wu HF; Yago MR; Xu X; Kadiyala P; Frassetto LA; Benet LZ
    Pharm Res; 2017 Mar; 34(3):619-628. PubMed ID: 28028768
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mechanistic investigation of the negative food effect of modified release zolpidem.
    Andreas CJ; Pepin X; Markopoulos C; Vertzoni M; Reppas C; Dressman JB
    Eur J Pharm Sci; 2017 May; 102():284-298. PubMed ID: 28286289
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Early pharmaceutical profiling to predict oral drug absorption: current status and unmet needs.
    Bergström CA; Holm R; Jørgensen SA; Andersson SB; Artursson P; Beato S; Borde A; Box K; Brewster M; Dressman J; Feng KI; Halbert G; Kostewicz E; McAllister M; Muenster U; Thinnes J; Taylor R; Mullertz A
    Eur J Pharm Sci; 2014 Jun; 57():173-99. PubMed ID: 24215735
    [TBL] [Abstract][Full Text] [Related]  

  • 35. In-vitro simulation of luminal conditions for evaluation of performance of oral drug products: Choosing the appropriate test media.
    Markopoulos C; Andreas CJ; Vertzoni M; Dressman J; Reppas C
    Eur J Pharm Biopharm; 2015 Jun; 93():173-82. PubMed ID: 25836053
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Improving Dissolution Behavior and Oral Absorption of Drugs with pH-Dependent Solubility Using pH Modifiers: A Physiologically Realistic Mass Transport Analysis.
    Salehi N; Kuminek G; Al-Gousous J; Sperry DC; Greenwood DE; Waltz NM; Amidon GL; Ziff RM; Amidon GE
    Mol Pharm; 2021 Sep; 18(9):3326-3341. PubMed ID: 34428047
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Predicting pharmacokinetic food effects using biorelevant solubility media and physiologically based modelling.
    Jones HM; Parrott N; Ohlenbusch G; Lavé T
    Clin Pharmacokinet; 2006; 45(12):1213-26. PubMed ID: 17112297
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Impact of phospholipid digests and bile acid pool variations on the crystallization of atazanavir from supersaturated solutions.
    Enright EF; Joyce SA; Gahan CGM; Taylor LS
    Eur J Pharm Biopharm; 2020 Aug; 153():68-83. PubMed ID: 32473291
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Assessment of Bioequivalence of Weak Base Formulations Under Various Dosing Conditions Using Physiologically Based Pharmacokinetic Simulations in Virtual Populations. Case Examples: Ketoconazole and Posaconazole.
    Cristofoletti R; Patel N; Dressman JB
    J Pharm Sci; 2017 Feb; 106(2):560-569. PubMed ID: 27865610
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The effect of food on the absorption and pharmacokinetics of rivaroxaban.
    Stampfuss J; Kubitza D; Becka M; Mueck W
    Int J Clin Pharmacol Ther; 2013 Jul; 51(7):549-61. PubMed ID: 23458226
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.